Trial · NCT01568944

Role of Infected Blood Dendritic Cells in Heart Disease Risk

NCT01568944, Not applicable, Completed, Augusta University; results first posted 2020-05-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Role of Infected Blood Dendritic Cells in Heart Disease Risk. Trials, record NCT01568944. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01568944

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Role of Infected Blood Dendritic Cells in Heart Disease Risk
NCT number: NCT01568944
Status: Completed
Phases: Not applicable
Enrollment: 18 participants, actual
Lead sponsor: Augusta University
Conditions: Chronic Periodontitis
Interventions: Oral Antibiotic and Oral Rinse, Standard Treatment
First posted: 2012-04-02
Last updated: 2020-05-12
Results first posted: 2020-05-12

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Frequency of Blood Dendritic Cells From Baseline	30 days	The frequency of blood dendritic cells, i.e. % CCR6+CD1a+ DCs by flow cytometry 30 days after treatment with 7 day regimen of antibiotics, mouthrinse therapy and scaling and root planing (SRP) will be compared to those who did not receive the antibiotics, but did receive mouthrinse and scaling and root planing (SRP)
Secondary	Probing Attachment Levels	30 days	Probing attachment levels (distance from the cemento-enamel junction to the base of the periodontal pocket in mm at 6 sites p\[er tooth) will be monitored after 30 days
Secondary	Serum Cytokine Response	30 days	serum CCL20 in pg/ml by ELISA will be measured after 30 days
Secondary	Probing Depths	30 days	Probing depths (distance from the free gingival margin to the base of the pocket in mm at six sites per tooth) will be monitored after 30 days
Secondary	Plaque Index	30 days	Plaque index of Silness and Loe will be monitored at buccal and lingual surfaces of all teeth after 30 days: 0 no visible microbial plaque 1. thin film of visible microbial plaque in sulcus 2. moderate accumulation of plaque in sulcus 3. large amount of plaque in sulcus or along free gingival margin
Secondary	Gingival Index	30 days	Gingival index of Loe and Silness on facial, lingual and mesial surfaces of all teeth will be monitored after 30 days: 0 Normal, no inflammation 1. Mild inflammation, slight color change and edema, no bleeding 2. Moderate inflammation, redness, edema, bleeds on probing 3. Severe inflammation, marked redness and edema ulceration, spontaneous bleeding

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Frequency of Blood Dendritic Cells From Baseline	30 days		% MFI	MEAN
SECONDARY	Probing Attachment Levels	30 days	The number of teeth	mm	MEAN
SECONDARY	Serum Cytokine Response	30 days	CCL20 in pg/ml of serum will be measured by ELISA	pg/ml	MEAN
SECONDARY	Probing Depths	30 days	Probing depths in mm at 192 sites per patient	mm	MEAN
SECONDARY	Plaque Index	30 days	plaque index at 64 sites per mouth will be measured	pI index	MEDIAN
SECONDARY	Gingival Index	30 days	gingival index at 3 sites per tooth	GI	MEDIAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Frequency of Blood Dendritic Cells From Baseline	Oral Antibiotic and Oral Rinse	12	Standard Deviation 4	% MFI
Frequency of Blood Dendritic Cells From Baseline	Standard Treatment	14	Standard Deviation 2	% MFI
Probing Attachment Levels	Oral Antibiotic and Oral Rinse	4.2	Standard Deviation 6	mm
Probing Attachment Levels	Standard Treatment	4.6	Standard Deviation 4	mm
Serum Cytokine Response	Oral Antibiotic and Oral Rinse	22	Standard Deviation 5	pg/ml
Serum Cytokine Response	Standard Treatment	32	Standard Deviation 5	pg/ml
Probing Depths	Oral Antibiotic and Oral Rinse	4.2	Standard Deviation 3	mm
Probing Depths	Standard Treatment	4.7	Standard Deviation 4	mm
Plaque Index	Oral Antibiotic and Oral Rinse	2	90% Confidence Interval 0 to 3	pI index
Plaque Index	Standard Treatment	3	90% Confidence Interval 1 to 3	pI index

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Oral Antibiotic and Oral Rinse	8
Overall Study	STARTED	Standard Treatment	10
Overall Study	COMPLETED	Oral Antibiotic and Oral Rinse	8
Overall Study	COMPLETED	Standard Treatment	10
Overall Study	NOT COMPLETED	Oral Antibiotic and Oral Rinse	0
Overall Study	NOT COMPLETED	Standard Treatment	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Oral Antibiotic and Oral Rinse	8
Total, all-cause mortality	Standard Treatment	8
Total, other adverse events	Oral Antibiotic and Oral Rinse	8
Total, other adverse events	Standard Treatment	8
Total, serious adverse events	Oral Antibiotic and Oral Rinse	8
Total, serious adverse events	Standard Treatment	8

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
20562309	BACKGROUND	PubMed
21523219	BACKGROUND	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R21DE020916	Peripheral blood dendritic cells and periodontitis	CUTLER, CHRISTOPHER WILLIAM	AUGUSTA UNIVERSITY	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH	2011 to 2012

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Oral Antibiotic and Oral Rinse vs Standard Treatment: deaths from any cause	Trial comparisons
Oral Antibiotic and Oral Rinse vs Standard Treatment: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01568944

GET https://conductscience.org/api/trials/v1/NCT01568944/registered

API reference For AI assistants